654 related articles for article (PubMed ID: 15700491)
1. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
2. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
Andersen M; Dahlstrand C; Høye K
Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
[TBL] [Abstract][Full Text] [Related]
3. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Kirby RS; O'Leary MP; Carson C
BJU Int; 2005 Jan; 95(1):103-9; discussion 109. PubMed ID: 15638905
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
Sun GH; Tsui KH; Wu TT; Chang CH; Cheng CL; Schou M
Kaohsiung J Med Sci; 2010 Oct; 26(10):532-9. PubMed ID: 20950778
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
14. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
15. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
Zhang K; Yu W; Jin J; Ye H; Wang X; Zhang N; Yang Y; Zhong C; Wan B
Urology; 2011 Sep; 78(3):636-40. PubMed ID: 21696807
[TBL] [Abstract][Full Text] [Related]
16. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
[TBL] [Abstract][Full Text] [Related]
17. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
18. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
[TBL] [Abstract][Full Text] [Related]
19. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
20. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
Ng CF; Wong A; Cheng CW; Chan ES; Wong HM; Hou SM
J Urol; 2008 Sep; 180(3):1042-6. PubMed ID: 18639296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
